Big Pharma firms back $43M round for NeuroTherapeutics

Chicago-based start-up NeuroTherapeutics Pharma has snagged a hefty $43 million Series B from a group of top biotech venture groups, including the venture arms of a pair of Big Pharma companies. The money will fund development of the company's lead central nervous system drug through multiple proof-of-concept studies. And the company is boasting that it has a platform that can deliver drugs for a broad range of disease targets, from epilepsy to pain and other CNS conditions.

Fidelity Biosciences, MPM Capital and SR One, the venture arm of GlaxoSmithKline, co-led the transaction, with Pfizer jumping on board as well. Existing investors Novo Ventures and Thomas McNerney & Partners also participated in the round.

"In preclinical studies, the company has shown that its compounds have the potential to create new therapies for patients suffering from epilepsy, neuropathic and acute pain that significantly improve upon those that are currently available. This large investment in NTP speaks to that unmet need as well as to the company's potential to transform the marketplace by developing therapies that act in a new way," said NTP CEO Stephen Collins, MD, PhD.

According to NTP's website, Collins had been chief scientific officer and VP of clinical affairs of Ovation Pharmaceuticals, a CNS-focused biopharmaceutical company acquired by Lundbeck A/S for $900 million. The developer named the ubiquitous Corey Goodman, Pfizer's former biotech chief, to the board last October.

- here's NTP's press release

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.